Hereditary-patterned baldness, or androgenetic alopecia, affects nearly 40 per cent of people worldwide, often beginning in their 30s and progressing with age. Despite its prevalence, treatment options remain limited. While topical minoxidil is one of the few FDA-approved solutions, its poor solubility and weak skin absorption limit its effectiveness. Researchers at the University of Sydney discovered that stevioside, a natural ...